Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ChemoCentryx, Inc.
After the historic approvals of Seres’ and Ferring’s microbiome-based treatments for recurrent Clostridioides difficile infection, the two companies are waiting to see who dominates the $1bn market. Physicians say patients will steer the choice of treatments.
Freed from a lengthy FDA clinical hold, the French biotech is advancing on a variety of fronts, business development head Savita Bernal tells Scrip.
Public Company Edition: J&J’s consumer health spinout Kenvue grossed $3.8bn in its public market debut and Acelyrin raised $540m in an upsized IPO. Also, Seres accessed $250m in new debt for Vowst commercialization while follow-on offerings raised $325m for ImmunoGen and $240m for Morphic.
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
- Drug Discovery Technologies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.